Axim Biotechnologies, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
8-K: AXIM Biotechnologies Announces Change of Control, New President and Director Following Death of CEO
AXIM Biotechnologies experienced a change of control with the transfer of Series C Preferred Stock, appointed a new President, Catalina Valencia, and a new Series C Director, also Catalina Valencia, following the death of former President and CEO John W. Huemoeller II.
OID
AXIM Biotechnologies issued convertible notes and restricted stock totaling $825,555 to settle past due compensation with directors, officers, contractors, and employees.
OID
AXIM Biotechnologies has reached a settlement in a legal dispute, agreeing to pay cash, sales participation, and issue restricted shares.